# Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer

> **NCT04157491** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 23 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** anlotinib and anti PD-1 antibody

## Key facts

- **NCT ID:** NCT04157491
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-18
- **Primary completion:** 2020-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157491, "Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04157491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*